Safety, censoring, and intent-to-treat analysis: dangers to generalizability.
Boulware
David R
DR
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000188:drug therapy* / Q000401:mortality; D017954:Africa South of the Sahara; D000410:Alanine Transaminase / Q000097:blood; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects* / Q000379:methods; D015725:Fluconazole / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008099:Liver / Q000187:drug effects; D008111:Liver Function Tests; D016919:Meningitis, Cryptococcal / Q000150:complications* / Q000188:drug therapy* / Q000401:mortality; D019829:Nevirapine / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics
D019380:Anti-HIV Agents; D000935:Antifungal Agents; D015725:Fluconazole; D019829:Nevirapine; D000410:Alanine Transaminase